Welcome to our dedicated page for Portage Biotech news (Ticker: PRTG), a resource for investors and traders seeking the latest updates and insights on Portage Biotech stock.
Portage Biotech Inc. develops clinical-stage immuno-oncology therapies for cancer, with news centered on its multi-targeted pipeline and related financing, listing and governance developments. Company updates describe biologic and small-molecule programs including PORT-6, a selective A2A antagonist, and PORT-7, a selective adenosine A2B receptor inhibitor, with disclosures covering combination approaches, preclinical mesothelioma data and the ADPORT-601 clinical program.
Recurring Portage news also includes fiscal-year financial results, research and development expense trends, Nasdaq continued-listing compliance and ordinary-share transactions, including stock-for-stock investment activity involving Compedica Holdings Limited.
Portage Biotech Inc. (NASDAQ: PRTG) announces participation in investor conferences in September 2021, enhancing investor outreach. Management will present at three notable events: the H.C. Wainwright 23rd Annual Global Investor Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, and the 2021 Cantor Virtual Global Healthcare Conference on September 29. Recordings of the Oppenheimer and Cantor presentations will be archived on Portage's website. The company focuses on immuno-oncology therapies targeting cancer treatment resistance.
Portage Biotech (NASDAQ: PRTG) reported raising $29 million to expedite its clinical pipeline focused on cancer treatment innovation. The funding enables advancement of Phase 1 and Phase 2 trials for lead iNKT agonists PORT-2 and PORT-3. Despite a net loss of $3.2 million for the quarter ending June 30, 2021, up from $0.7 million the prior year, the company’s cash balance was approximately $28.6 million. The company plans to present its advancements at several upcoming conferences, further enhancing its visibility in the immuno-oncology sector.
Portage Biotech Inc. (NASDAQ: PRTG) provided a corporate update reflecting significant advancements in its immuno-oncology pipeline. The company has successfully transitioned three assets into clinical trials, raising over $29 million since March 31, 2021, including a $26.5 million public offering. Portage aims to leverage novel iNKT agonists for treating cancer, with two lead assets, PORT-2 and PORT-3, currently in clinical trials. The company anticipates multiple data readouts in the upcoming 12-24 months, supported by enhanced investor relations and strategic partnerships.
Portage Biotech Inc. (NASDAQ: PRTG) has initiated the first patient dosing in the Oxford-led IMP-MEL study, a clinical trial assessing the safety and efficacy of PORT-2, an iNKT agonist for treating solid tumors. Preclinical results indicate PORT-2 promotes strong immune responses and may enhance the effectiveness of PD-1 inhibitors like Keytruda. The study will enroll 100 patients and aims to evaluate PORT-2 both alone and in combination with checkpoint therapies. Positive preclinical data positions PORT-2 as a potential solution for checkpoint-resistant tumors, bolstering its clinical importance.
Portage Biotech (NASDAQ: PRTG) reported a transformative year in its press release dated July 28, 2021, detailing significant corporate and clinical milestones for the fiscal year ended March 31, 2021. The company raised over $29 million, ensuring a two-year cash runway for ongoing clinical trials. Despite a net loss of $17.2 million, an increase from $7.2 million the previous year, Portage is advancing its lead iNKT agonists and presented positive interim data from clinical trials. With a focus on immuno-oncology, the company has divested legacy businesses to concentrate on high-potential assets.